Antisense inhibition of amphiregulin expression reduces EGFR phosphorylation in transformed human breast epithelial...

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Epidermal Growth Factor Receptor (EGFR) activation is crucial for cancer metastasis.
• Clinical response to EGFR inhibitors in breast cancer is limited.
• Amphiregulin (AR) is an EGFR ligand that may influence treatment efficacy.

Purpose of the Study:

• To investigate the role of amphiregulin (AR) in modulating EGFR activation in breast cancer.
• To explore the potential of targeting AR as an anti-EGFR therapeutic strategy.

Main Methods:

• Utilized antisense cDNA technique to down-regulate AR or EGFR expression in NS2T2A1 mammary tumor cells.
• Assessed matrix metalloproteinase-9 production and cell proliferation.
• Evaluated EGFR protein levels and tyrosine phosphorylation in response to EGF stimulation.

Main Results:

• Down-regulation of AR or EGFR significantly inhibited matrix metalloproteinase-9 production and cell proliferation.
• Exogenous addition of AR or EGF minimally reversed the inhibition.
• EGFR protein levels remained unchanged, but EGF-induced EGFR-tyrosine phosphorylation was markedly reduced.

Conclusions:

• Inhibition of AR expression impairs EGFR response to available ligands.
• Targeting AR represents a potential alternative anti-EGFR therapeutic strategy for breast cancer.